.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,702,716

« Back to Dashboard

Details for Patent: 5,702,716

Title: Polymeric compositions useful as controlled release implants
Abstract:The invention is directed to an improved system for controlled release of biologically active materials and to a liquid composition for its formation. The liquid composition is composed of a thermoplastic polymer, rate modifying agent, bioactive material and organic solvent. The liquid composition is capable of forming a biodegradable and/or bioerodible microporous, solid polymer matrix. The matrix is useful as an implant in patients (humans and animals) for delivery of biologically active substances to tissues or organs.
Inventor(s): Dunn; Richard L. (Fort Collins, CO), Tipton; Arthur J. (Fort Collins, CO)
Assignee: Atrix Laboratories, Inc. (Fort Collins, CO)
Filing Date:Jun 02, 1993
Application Number:08/070,498
Claims:1. A thermoplastic polymer system suitable as a controlled release implant, comprising:

a solid, microporous matrix of a pharmaceutically acceptable, biodegradable thermoplastic polymer which is insoluble in aqueous medium or human or animal body fluids, a biologically active agent, and up to about 15% by weight of a pharmaceutically acceptable, water-insoluble, rate-retarding agent which retards the rate of release of the biologically active agent from the matrix up to 100 fold relative to its rate of release from the same matrix without the rate-retarding agent, and which imparts a Tg to the matrix of less than about 55.degree. C., the weight being relative to the total weight of the matrix; and,

the microporous matrix being formed externally or in situ respectively by a process comprising combining a composition with the aqueous medium, or administering the composition directly into a body tissue or cavity having the human or animal body fluids;

the composition comprising the thermoplastic polymer, the biologically active agent, the rate-retarding agent and a pharmaceutically acceptable organic solvent in which the thermoplastic polymer, biologically active agent and rate-retarding agent are dissolved or dispersed, the organic solvent being miscible to dispersible in aqueous medium or human or animal body fluids;

the combining step or administering step resulting in diffusion of the organic solvent into the aqueous medium or body fluid and resulting in coagulation of the thermoplastic polymer to form the solid microporous matrix;

the thermoplastic polymer being selected from the group consisting of polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyothoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), and copolymers, terpolymers and any combination thereof, and the thermoplastic polymer having a molecular weight up to about 0.8 inherent viscosity; and,

the rate-retarding agent being selected from the group consisting of an ester of a mono, di or tricarboxylic acid, a polyhydroxy alcohol, a fatty acid, a fatty acid ester, an epoxidized oil, a sterol, a higher alkyl alcohol, and any mixture thereof.

2. A system according to claim 1 wherein the rate-retarding agent is less water-soluble than the organic solvent.

3. A system according to claim 1 wherein the solvent is selected form the group consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone, ethanol, propylene glycol, acetone, acetic acid, ethyl acetate, ethyl lactate, methyl acetate, methyl ethyl ketone, dimethylformamide, dimethyl sulfoxide, dimethyl sulfone, tetrahydrofuran, propylene carbonate, caprolactam, decylmethylsulfoxide, oleic acid, N,N-diethyl-m-toluamide, and t-dodecylazacycloheptan-2-one, and any combination thereof.

4. A system according to claim 1 wherein the rate-retarding agent is selected from the group consisting of ethyl heptanoate, glycerin, diethyl citrate, and triethyl citrate.

5. A system according to claim 1 further comprising a pore forming agent.

6. A system according to claim 1 wherein the matrix comprises a core and skin, the core being microporous and the skin having pores of substantially smaller size than the core.

7. A system according to claim 1 wherein the thermoplastic polymer is polylactide, polyglycolide, polycaprolactone or a copolymer of any combination of lactide, glycolide and caprolactone monomer.

8. A composition suitable for formation of a controlled release implant for use in a patient, comprising:

a) a pharmaceutically acceptable, biodegradable thermoplastic polymer that is insoluble in aqueous medium or human or animal body fluid;

b) a biocompatible organic solvent that is miscible to dispersible in water or human or animal body fluids;

c) a biologically active compound;

d) up to about 15% by weight of a pharmaceutically acceptable, water-insoluble, rate-retarding agent which remains in the implant after the formation of the implant from the composition, which imparts a Tg to the implant of less than about 55.degree. C., and which retards the rate of release of the biologically active compound from the implant up to 100 fold relative to the rate of release of the biologically active compound from the same implant without the rate-retarding agent when the implant is made externally or in situ respectively by combining the composition and the aqueous medium or by administering the composition directly to a body tissue or cavity having the human or animal body fluids, the weight being relative to the sum of the weights of the thermoplastic polymer, the biologically active agent and the rate retarding-agent:

the combining step or administering step resulting in diffusion of the organic solvent into the aqueous medium or body fluid and resulting in coagulation of the thermoplastic polymer to form the solid microporous matrix:

the thermoplastic polymer being selected from the group consisting of polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyothoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), and copolymers, terpolymers and any combination thereof and the thermoplastic polymer having a molecular weight up to about 0.8 inherent viscosity; and,

the rate-retarding agent being selected from the group consisting of an ester of a mono, di or tricarboxylic acid, a polyhydroxy alcohol, a fatty acid, a fatty, acid ester, an epoxidized oil, a sterol, a higher alkyl alcohol, and any mixture thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc